LT - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases
EN - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases
Legal status
Patent not validated
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 38/01 |
|
|
|
A61K 38/03 |
|
|
|
A61K 38/04 |
|
|
|
A61P 9/00 |
|
|
|
A61P 11/00 |
|
|
|
A61P 17/00 |
|
|
|
A61P 25/00 |
|
|
|
A61P 31/12 |
|
|
|
A61P 37/00 |
|
European patent
| (11) |
Number of the document |
2650007 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
13002792.3 |
|
Date of filing the European patent application |
2009-06-02 |
| (97) |
Date of publication of the European application |
2013-10-16 |
| (45) |
Date of publication and mention of the grant of the patent |
2015-05-20
|
| (46) |
Date of publication of the claims translation |
|
Priority applications
| (30) |
Number |
Date |
Country code |
|
PCT/EP2008/0043 |
2008-05-30
|
WO |
Inventors
| (72) |
Bonny, Christophe, CH
|
Grantee
| (73) |
Xigen Inflammation Ltd.,
Arch. Makariou III 195 Neocleous House, 3030 Limassol,
CY
|
Title
| (54) |
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases |
| |
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various autoimmune diseases |
